Deborah Armstrong, MD, Chair/Moderator
Associate Professor of Oncology
Johns Hopkins Kimmel Cancer Center
Johns Hopkins University School of Medicine
James T. Thigpen, MD
Professor of Medicine
Department of Internal Medicine
University of Mississippi Medical Center
Judith K. Wolf, MD
Department of Gynecologic Oncology
University of Texas M.D. Anderson Cancer Center
THIS ACTIVITY WAS ORIGINALLY PRESENTED AS AN EDUCATONAL LUNCH SYMPOSIUM HELD IN CONJUNCTION WITH THE SOCIETY OF GYNECOLOGIC ONCOLOGISTS ANNUAL MEETING ON WOMEN'S CANCER IN TAMPA, FLORIDA ON MONDAY, MARCH 10, 2008. IF YOU RECEIVED CME CREDIT FOR ATTENDING THE LIVE EVENT, YOU ARE NOT ELIGIBLE TO RECEIVE CREDIT FOR THIS ONLINE RELEASE.
Ovarian cancer is the most common cause of death from gynecologic malignancies and remains the fifth leading cause of death from cancer in women in the United States. Approximately 22,430 women are diagnosed with ovarian cancer in the U.S. annually, and an estimated 15,280 die of this disease. Since there are no effective screening protocols in place, many women are diagnosed with this illness at advanced stages associated with poor prognosis. Following surgical diagnosis and staging, appropriate patients are debulked and managed with chemotherapy and supportive care. Unfortunately, many women develop persistent, recurrent, or refractory ovarian cancer. Because of the recent advancements in the management of these enduring forms of ovarian cancer, continuing education is needed to help clinicians understand all available treatment options.
Our expert faculty will discuss the currently available therapeutic agents for persistent, recurrent, and refractory ovarian cancer, the risk/benefits of combination therapy, second-line chemotherapy for platinum-sensitive and platinum-resistant disease, and promising agents currently under investigation.
Through presentation of case studies, the faculty will emphasize the importance of establishing individualized treatment plans for each patient and will encourage clinicians to explore all the available options for their patients.
. Target Audience
This program is designed for medical oncologists and other health care professionals involved in the treatment of ovarian cancer.
Upon completion of this educational activity, the participant should be able to:
Summarize overall treatment goals and strategies for patients who develop persistent, recurrent, or refractory disease.
Describe the data comparing the use of single agent versus combination chemotherapy regimens when treating recurrent ovarian cancer.
Describe the role of debulking surgery and radiotherapy for the management of recurrent ovarian cancer.
Select optimal chemotherapy regimens for persistent, recurrent, and refractory ovarian cancer based on recent evidence reflecting clinical efficacy, safety, and the impact on quality of life.
Identify approaches to assessing chemotherapy response, including the use of serum markers, laboratory assays, imaging studies, and other techniques.
It is the policy of AKH Inc. to ensure independence, balance, objectivity, scientific rigor, and integrity in all of their continuing education activities. The faculty must disclose to the participants any significant relationships with commercial interests whose products or devices may be mentioned in the activity or with the commercial supporter of this continuing education activity. Identified conflict of interest is resolved by AKH prior to accreditation of the activity. Faculty members are expected to openly disclose any off-label, experimental, or investigational use of drugs or devices in their presentations.
Deborah K. Armstrong, MD discloses that she has participated in advisory committees for TriPath, Biogen Idec, Genentech, Bayer/Onyx, and Cephalon.
James T. Thigpen, MD discloses that he is a member of speakers bureaus with Genentech, GlaxoSmithKline, Eli Lilly and Company, Medimmune, and Ortho Biotech and has served as a consultant for Bristol-Myers Squibb, Berlex, Bionumerik, Celgene, Cell Therapeutics, EMD Biosciences, Genentech, GlaxoSmithKline, Eli Lilly and Company, McNeil Pharmaceutical, Novartis, Ortho Biotech, Telik, and sanofi-aventis.
Judith K. Wolf, MD discloses that she is a member of speakers bureaus with Eli Lilly and Company, GlaxoSmithKline, Ortho Biotech, and Merck & Co. Credit Statements
This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint sponsorship of AKH Inc. and Medical Communications Media, Inc. AKH Inc. is accredited by the ACCME to provide continuing medical education for physicians.
AKH Inc. designates this educational activity for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should only claim credit commensurate with the extent of their participation in the activity.
Credit is awarded to participants who listen to the presentation and complete the post-test with a minimum score of 70% and the activity evaluation. There is no fee to participate. Commercial Support Statements
This program is supported by an educational grant from Eli Lilly and Company.
Please turn off all pop-up blockers.
Click on the “start program” icon. This will bring you to the login/registration page where you will be able to register as a new CMEcorner.com member or update/correct existing registration information. When ready, click on the “continue to program” icon at the bottom of the screen. This will take you to a brief pre-program survey.
The next screen will permit you to check for or download the Flash player required to run this program.
Clicking “start the virtual meeting” will allow you to begin the program presentation. The program will require approximately 60 minutes to complete.
Upon completion of the program, click on the post-test button to access the post-test and program evaluation. This will bring you to a brief post-program survey followed by the post-test and evaluation.
Instructions for completing and submitting the post-test are provided on the post-test screen. A minimum score of 70% on the post-test is required for a CME statement of credit. Two attempts are allowed.
©2008, Medical Communications Media, Inc. All rights reserved. None of the contents may be reproduced in any form without prior written permission from the publisher. The opinions expressed in this activity are those of the presenters and do not necessarily reflect the opinions or recommendations of their affiliated institutions, the publisher, AKH Inc., the Society of Gynecologic Oncologists, or Eli Lilly and Company. Any medications or other diagnostic or treatment procedures discussed by the program faculty should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or risks, and without a review of any applicable manufacturer’s product information and comparison with the recommendations of other authorities.